肝细胞癌MRI:东西方趋势与机遇的跨区域视角
本文从跨区域视角总结肝细胞癌MRI在监测、诊断与疗效评估中的东西方差异。东亚地区重视诊断敏感性,采用更宽的MRI筛查标准;西方地区因优先考虑肝移植而强调高特异性与更严格的「确定HCC」标准。疗效评估标准已趋于全球一致,从测量肿瘤大小缩减转向基于肿瘤活性特征的评估。
要点
- 东亚指南强调高诊断敏感性,MRI筛查指征更宽。
- 西方指南强调高特异性,确定HCC标准更严格。
- 疗效评估已由大小测量转向肿瘤活性特征判断。
核心结论
- 东西方HCC管理在MRI使用上差异明显,反映疾病流行、治疗模式及报销政策的区域差异。
- 诊断标准在东西方仍存在一定分歧,但疗效评估标准已在全球范围内同步演变。
研究设计与样本
- 本文为Radiographics刊出的跨区域视角综述,作者比较东西方医疗体系中MRI用于HCC监测、诊断和治疗监测的差异。
- 以国家或区域性实践指南作为区域实践模式的代表性依据。
诊断标准与关键数值
- 东亚地区以乙型肝炎为主要病因且局部消融优先,指南强调高诊断敏感性,采用更宽的MRI筛查条件。
- 西方地区优先考虑肝移植且对特异性要求高,指南强调高验前概率并对「确定HCC」采用更严格标准。
- 疗效评估标准已由测量肿瘤总体缩小转向基于肿瘤活性特征进行评估。
临床应用与阅片要点
- 解读多中心国际研究时应识别区域实践差异,避免直接混用不同区域的诊断与监测策略。
- 应用免疫治疗时,常规大小标准可能低估疗效,应结合肿瘤活性特征评估治疗获益。
- 在日常报告中,应结合所在区域的指南选用与诊断敏感性和特异性相匹配的MRI判读标准。
局限性
- 不同区域甚至同一国家内部也存在实践差异,难以形成完全统一的结论。
- 本文以国家和地区指南代表区域实践,可能无法覆盖指南以外的实际临床变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Management of hepatocellular carcinoma (HCC) can vary substantially by region. The authors highlight differences between Eastern and Western health care systems in the use of MRI for surveillance, diagnosis, and treatment monitoring in patients with HCC. These regional differences reflect variations in disease prevalence, treatment practice patterns, and reimbursement policies as well as the evolving role of MRI in the care continuum, for which global consensus has not yet been achieved. Although variations are not uncommon, even within regions or countries, some general observations can be made and are represented by national or regional practice guidelines. For instance, in East Asia, where hepatitis B is the predominant cause of HCC and locoregional tumor ablation is preferred, guidelines emphasize high diagnostic sensitivity. Consequently, they employ broader screening criteria with MRI. Conversely, in Western regions where liver transplant for HCC is prioritized and the stakes for specificity are high, guidelines emphasize high pretest probabilities and stricter criteria for "definite HCC." Although HCC diagnostic criteria remain somewhat divergent, the criteria for assessment of treatment response have transcended regional differences to evolve globally in tandem, shifting away from measuring the gross reduction in tumor size toward assessment based on features of tumor viability. This shift has been instrumental for adoption of immunotherapy, in which conventional size criteria may allow underestimation of its therapeutic benefit. Recognition of these regional variations is important in interpretation of multicenter international studies and to facilitate global collaboration in MRI-based management of HCC.
引用
- Tan, Jiang, Wang, et al. MRI of Hepatocellular Carcinoma: Cross-regional Perspectives on Trends and Opportunities. Radiographics. 2026. PMID: 42658729. doi:10.1148/rg.260001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。